There are no official guidelines to assist in answering this question. I will search for relevant research papers instead.
From the Research
Current mRNA Vaccines
The following vaccines are currently being manufactured using Messenger RNA (mRNA) technology:
- COVID-19 vaccines, which have shown more than 90% protective efficacy against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection 1
- Seasonal influenza vaccines 2
- Vaccines against Epstein-Barr virus 2, 3
- Vaccines against human immunodeficiency virus (HIV) 2, 3
- Vaccines against respiratory syncytial virus, Nipah virus, Zika virus, and human cytomegalovirus 3
mRNA Vaccine Platforms
There are several mRNA vaccine platforms currently being developed, including:
- Nucleoside-modified mRNA vaccines 1
- Unmodified mRNA vaccines 1
- Circular RNA vaccines 1
- Self-amplifying RNA vaccines 1
Clinical Progress and Future Prospects
The clinical progress of mRNA vaccines has been significant, with several vaccines currently in clinical development 4, 2. The future prospects of mRNA vaccines are promising, with potential applications in the prevention of various viral infections, including those for which classical formulations are already authorized 3. However, there are still challenges to be met, such as storage conditions and immunogenicity of some components of lipid nanoparticles 3.